Antibody-drug conjugates (ADCs) 定制

抗體藥物結合物（ADC）定制

are new-generation anti-cancer immunotherapeutic agents that accurately deliver cytotoxic agents to cancer cells to achieve caner elimination without damaging normal tissues. ADCs carry extremely high potent toxins and their pharmacokinetic properties and safety profile need to be extensively evaluated before deploying to human clinical trials. One crucial aspect in ADC pharmacokinetic (PK) property is the ratio of total and conjugated antibody after certain time period of deployment. This is usually assayed using immuno-colorimetric assay methods such as ELISA. To detect and quantify conjugated antibody, an agent that targets the drug portion of the ADC is desired.

是新一代抗癌免疫治療劑，能夠準確地將細胞毒性藥物輸送到癌細胞，從而在不損害正常組織的情況下消除癌癥。ADC攜帶極強的毒素，在用于人體臨床試驗之前，需要對其藥代動力學特性和安全性進行廣泛評估。ADC藥代動力學（PK）特性的一個關鍵方面是在一定時間部署后總抗體和結合抗體的比率。通常使用免疫比色分析法（如ELISA）進行檢測。為了檢測和量化結合抗體，需要一種針對ADC藥物部分的試劑。

Due to the high potency of ADC toxins, antibodies against these chemical compounds are difficult to develop. Only low dosages of a toxin can be applied for animal immunization and the corresponding immune response is low in small rodents. After devoting a tremendous amount of effort, Creative Biolabs has raised a series of antibodies, collectively anti-drug Abs, against ADC toxin antigens include MMAE, MMAF, DM1, DM4, Calicheamicin, Duocarmycin…. These anti-drug Abs will be valuable assets to facilitate the PK and safety evaluation of newly developed ADCs bearing these drugs.

由于ADC毒素的高效價，很難產生針對這些化合物的抗體。只有低劑量的毒素才能用于動物免疫，而小嚙齒類動物的相應免疫反應較低。經過大量努力，Creative Biolabs已經研發出一系列抗體，統稱為抗藥物抗體，針對ADC毒素抗原，包括MMAE、MMAF、DM1、DM4、卡利霉素、杜卡霉素…。這些抗藥物抗體將是有價值的資產，有助于對攜帶這些藥物的新開發ADC進行PK和安全性評估。